News releases

Toronto – March 3, 2025 – Biosimilars Canada is pleased to announce the unanimous election of Mike Casia, President and Managing Director of Organon Canada, as Chair of Biosimilars Canada for 2025. Mike Woolcock, Senior Vice President of Biosimilars and Specialty...

Toronto – November 14, 2024 – Biosimilars Canada has launched a new #SaveBigWithBiosimilars campaign to educate Canadian businesses about the benefits of adopting biosimilar transition policies for their employee health benefit plans. While public drug programs across Canada have adopted...

All Ten Canadian Provinces Have Now Made the Switch to Biosimilars Toronto – August 6, 2024 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the Government of Manitoba that it has implemented a...

Toronto – May 7, 2024 – Biosimilars Canada is pleased to announce the unanimous re-election of Mr. Mike Woolcock, Senior Vice President of Biosimilars and Specialty Products with Apotex, as Chair of the Biosimilars Canada Board. Mr. Mike Casia, President...

The generic and biosimilar medicines industries will need to learn more about the Government of Canada’s approach to implementation, and consult with key stakeholders, to help ensure that a transition to this program would maximize the use of cost-saving generic and biosimilar medicines, while protecting Canada’s drug supply and domestic manufacturing capacity.

Toronto – October 12, 2023 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the Government of Prince Edward Island (PEI) that it is implementing a “switching” or transitioning policy to expand the use...